Ocular Therapeutix Inc (NASDAQ: OCUL) is 52.46% higher on its value in year-to-date trading and has touched a low of $5.78 and a high of $11.77 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The OCUL stock was last observed hovering at around $8.13 in the last trading session, with the day’s loss setting it -6.15%.
Currently trading at $1.98M, the stock is 0.38% and 6.59% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.72 million and changing 1717949% at the moment leaves the stock -0.92% off its SMA200. OCUL registered -1.99% loss for a year compared to 6-month loss of -7.21%. The firm has a 50-day simple moving average (SMA 50) of $7.8523 and a 200-day simple moving average (SMA200) of $8.44735.
The stock witnessed a 14.66% gain in the last 1 month and extending the period to 3 months gives it a 11.45%, and is -4.12% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.53% over the week and 3.96% over the month.
Ocular Therapeutix Inc (OCUL) has around 274 employees, a market worth around $1.33B and $59.65M in sales. Profit margin for the company is -323.09%. Distance from 52-week low is 44.68% and -28.92% from its 52-week high. The company has generated returns on investments over the last 12 months (-56.68%).
with sales reaching $13.12M over the same period.The EPS is expected to shrink by -17.19% this year, but quarterly earnings will post -13.55% year-over-year. Quarterly sales are estimated to shrink -20.19% in year-over-year returns.
Ocular Therapeutix Inc (OCUL) Top Institutional Holders
256.0 institutions hold shares in Ocular Therapeutix Inc (OCUL), with institutional investors hold 90.25% of the company’s shares. The shares outstanding are 159.26M, and float is at 133.64M with Short Float at 10.67%. Institutions hold 87.01% of the Float.
The top institutional shareholder in the company is SUMMER ROAD LLC with over 14.89 million shares valued at $101.82 million. The investor’s holdings represent 8.9767% of the OCUL Shares outstanding. As of 2024-06-30, the second largest holder is VR ADVISER, LLC with 12.76 million shares valued at $87.3 million to account for 7.6964 of the shares outstanding. The other top investors are DEEP TRACK CAPITAL, LP which holds 12.72 million shares representing 7.6716% and valued at over $87.01 million, while BLACKROCK INC. holds 6.9473 of the shares totaling 11.52 million with a market value of $78.8 million.
Ocular Therapeutix Inc (OCUL) Insider Activity
The most recent transaction is an insider sale by Waheed Nadia,the company’sChief Medical Officer. SEC filings show that Waheed Nadia sold 13,861 shares of the company’s common stock on Jun 02 ’25 at a price of $8.05 per share for a total of $0.11 million. Following the sale, the insider now owns 0.21 million shares.
Still, SEC filings show that on May 23 ’25, Nayak Sanjay (Chief Strategy Officer) disposed off 1,862 shares at an average price of $7.17 for $13351.0. The insider now directly holds 281,623 shares of Ocular Therapeutix Inc (OCUL).
